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IL-18 Downregulates Collagen Production in Human
Dermal Fibroblasts via the ERK Pathway
Hee Jung Kim1, Seok Bean Song2, Jung Min Choi3, Kyung Moon Kim1, Baik Kee Cho1, Dae Ho Cho2 and
Hyun Jeong Park1
Excessive accumulation of collagen contributes to the fibrotic process. Several experimental studies have
shown that IFN-g is effective in preventing fibrogenesis. IL-18, originally identified as an IFN-g-inducing factor, is
a key mediator of inflammation and host defense responses. In this study, we investigated the regulatory effect
of IL-18 on the expression of type I and III collagen genes in dermal fibroblasts. The exposure of human dermal
fibroblasts (HDFs) to IL-18 resulted in a reduction of collagen gene expression and production. Also, IL-18
inhibited the fibrogenic cytokine transforming growth factor (TGF)-b-induced collagen gene expression. Next,
to determine the molecular mechanism involved in this regulation, we showed that IL-18-regulated collagen
expression was blocked by small interfering RNA (siRNA)-mediated Ets-1 knockdown. Furthermore, we showed
that IL-18 induced phosphorylation of extracellular signal-regulated kinase (ERK) within 10minutes and that the
ERK inhibitor PD98059 blocked the inhibitory effect of IL-18. IL-18 also inhibited the production of collagen in
systemic sclerosis (SSc) dermal fibroblasts. Our data indicate that IL-18 downregulates collagen production in
HDF directly via Ets-1 and the ERK pathway, suggesting that IL-18 may exert antifibrotic activities in dermal
fibroblasts.
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INTRODUCTION
A key feature of fibrosis is the excessive production of
extracellular matrix (ECM), mainly collagen (Uitto and
Kouba, 2000; Verrecchia and Mauviel, 2002a, b, 2004).
Excessive accumulation of collagen results in altered tissue
architecture and in disorders such as scleroderma, keloids,
hypertrophic scars, liver cirrhosis, and glomerulosclerosis
(Gruschwitz et al., 1990; Peltonen et al., 1990; Boker et al.,
1991; Trojanowska et al., 1998). Collagen consists mainly of
type I and III collagens, which constitute approximately 95%
of all known collagen types (Uitto et al., 1985). In healthy
skin, type I and III collagens exist in a ratio of approximately
4:1. Type I collagen is composed of glycine- and proline-rich
two-a1(I) and one-a2(I) chains (Ghosh, 2002).
Fibroblasts produce ECM proteins to perform its funda-
mental role in tissue homeostasis and normal wound repair
(Sorrell and Caplan, 2004). Systemic sclerosis (SSc) is a
connective-tissue disease characterized by progressive fibro-
sis of skin and internal organs (Medsger, 2000; Johnson et al.,
2002). It has been demonstrated that SSc fibroblasts show an
altered phenotype with an increased production of collagen
and a decreased level of matrix metalloproteinases, both of
which can contribute to an excessive accumulation of ECM
proteins (Takeda et al., 1994; Kuroda and Shinkai, 1997). It
was previously proposed that the initiation and progression of
fibrosis are affected by several growth factors and cytokines
released from inflammatory cells (Eckes et al., 2000).
Therefore, the identification of molecules that may negatively
affect the production of collagen is regarded as an important
therapeutic advance against fibrosis.
Various cytokines have been shown to regulate collagen
gene expression in fibroblasts. It has been demonstrated that
transforming growth factor (TGF)-b induces the synthesis of
many ECM proteins such as collagen, fibronectin, and
laminin and that it inhibits matrix-degrading enzymes and
has an important role in fibrosis, wound healing, and
tumorigenesis (Varga and Bashey, 1995; Branton and Kopp,
1999; Blobe et al., 2000). Riquet et al. (2000) reported that
IL-1b induces the synthesis of type I collagen in BALBc/3T3
fibroblasts. Mauviel et al. demonstrated that tumor necrosis
factor (TNF)-a inhibits type I collagen mRNA, as well as
protein, in dermal skin fibroblasts (Mauviel et al., 1991).
In vitro evidence of several cell lines suggests that IFN-g is a
potent inhibitor of collagen production (Mallat et al., 1995;
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Sakaida et al., 1998; Takahara et al., 2004). IL-18, a member
of the IL-1 family, was initially identified as an IFN-g-
inducing factor. It is produced by keratinocytes, intestinal
epithelial cells, dendritic cells, Kupffer cells, activated
monocytes/macrophages, osteoblasts, and adrenal cortex
cells (Okamura et al., 1995). IL-18 is a cytokine with
powerful T helper type 1 (Th1)-promoting activity in synergy
with IL-12 (Dinarello, 1999). It also promotes IFN-g, TNF-a,
and GM-CSF production and enhances the production of
anti-inflammatory or Th2 cytokines, such as IL-4, IL-10, and
IL-13 (Nakanishi et al., 2001). Recently, IL-18 was reported to
protect against bleomycin-induced lung injuries by inducing
a defensive molecule, Mn-containing superoxide dismutase
(Nakatani-Okuda et al., 2005). Investigating the molecular
mechanisms that lead to the upregulation of collagen
synthesis and cytokine-modulated collagen expression is
important to a better understanding of the causes of fibrosis.
Information concerning the effects of IL-18 on fibroblasts is
still limited, and the mechanism by which IL-18 acts against
fibrosis is not fully understood.
In this study, we investigated the effect of IL-18 on
collagen expression in human dermal fibroblasts (HDFs) and
SSc dermal fibroblasts and also examined the manner in
which IL-18 regulates collagen synthesis.
RESULTS
IL-18 inhibits collagen production in HDFs
The interactions between Th1 and Th2 cytokines have a
crucial role in the development of inflammation and fibrosis
(Wahl et al., 1997; Farah et al., 2000). Because IL-18 controls
multiple cytokines as it regulates Th1 and Th2 responses, we
tested whether IL-18 would affect the production and mRNA
levels of COL1A1, COL1A2, and COL3A1 in HDF. IL-18
binds to its specific receptor, IL-18R, which is expressed on
many cell types, including T cells, B cells, natural killer cells,
and epithelial and endothelial cells (Torigoe et al., 1997;
Born et al., 1998). To examine the expression of IL-18R in
HDFs, we performed reverse transcriptase (RT)-PCR and flow
cytometry analysis and found that IL-18R was expressed in
HDFs (Figure 1). Next, cells were treated with various doses
of IL-18 at each treatment time; thereafter, collagen mRNA
and collagen production were determined by real-time
RT-PCR and Sircol assay, respectively. As shown in Figure 2a,
treatment with 200 ngml1 IL-18 significantly reduced
COL1A1, COL1A2, and COL3A1 mRNA expression. The
time course of IL-18-induced collagen expression is shown in
Figure 2b. Treatment of HDF with IL-18 (200 ngml1)
significantly decreased collagen synthesis after 6 hours of
treatment, and collagen production was also dose-
dependently reduced in HDFs treated with IL-18 for 24 hours
(Figure 2c).
IFN-g inhibits collagen synthesis by fibroblasts in vitro
(Mallat et al., 1995; Sakaida et al., 1998; Takahara et al.,
2004); therefore, we tested whether IFN-g reduces collagen
expression in HDFs. Cells were treated with 1,000Uml1
of recombinant human IFN-g, which led to the suppression
of collagen expression in HDFs. Moreover, inhibited collagen
protein levels were observed 24 hours after treatment.
IFN-g and IL-18 inhibited both collagen gene expression
and protein production, in a similar manner (Figure 3).
Hence, we investigated whether there was a relationship
between these two cytokines in this process. Collagen
produced by fibroblasts incubated with or without a
neutralizing anti-IFN-g antibody in addition to IL-18
(200 ngml1) or IFN-g (1,000Uml1) was measured using
real-time RT-PCR and the Sircol assay (Figure 3a and b). The
collagen gene expression of HDFs that were treated with
IL-18 plus neutralizing anti-IFN-g antibody was higher than
that of cells treated with IFN-g plus neutralizing anti-IFN-g
antibody. These data suggest that the effect of IL-18 is
augmented by IFN-g.
It has recently become apparent that TGF-b is crucially
involved in fibrosis by enhancing the expression of several
collagens, including types I and III (Czaja et al., 1989;
Kawakami et al., 1998; Wang et al., 1999; Yamamoto et al.,
1999). We found that IL-18 suppresses the synthesis of
collagen types I and III and inhibits the secretion of collagen
treated with profibrotic cytokine TGF-b (Figure 4a and b). We
have shown here that IL-18 antagonizes the action of TGF-b
on collagen synthesis in HDFs.
Next, to examine whether the effect of IL-18 on collagen
gene expression takes place at the transcriptional level,
transient cell transfections were carried out with the collagen
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Figure 1. Expression of IL-18 receptor in human dermal fibroblasts (HDFs).
(a) HDFs were cultured in six-well plates. Total RNA was isolated from cells
using Trizol reagent, and cDNA was synthesized for reverse
transcriptase–PCR. PCR products were separated and visualized on 1.5%
agarose gel with ethidium bromide in Tris/borate/EDTA buffer. (b) Cells were
stained with mouse anti-human IL-18 (5 mg) and FITC-goat anti-mouse IgG
(1:100) as a secondary antibody. Cells were analyzed by indirect FACS.
A representative experiment of three independent experiments is shown.
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promoter/gene reporter constructs 2019 COL1A1/Luc and
2027 COL1A2/Luc. We found that treatment with IL-18
reduced the promoter activity of both COL1A1/Luc and
COL1A2/Luc. Furthermore, IL-18 suppressed induction of
COL1A1/Luc and COL1A2/Luc promoter activity after treat-
ment with TGF-b (Figure 5a and b). These data show that
IL-18 has a crucial role in the regulation of COL1A1/COL1A2
promoter activity.
Ets-1 is involved in IL-18-regulated collagen expression
Collagen genes are regulated by several transcription factors,
including Ets-1 (Czuwara-Ladykowska et al., 2002; Mizui
et al., 2006; Sherriff-Tadano et al., 2006). To determine
whether IL-18 alters collagen expression via regulation of
Ets-1, Ets-1 levels were compared under different stimulation
conditions. As shown in Figure 6a, treatment with IL-18
increased levels of Ets-1 protein. To examine the potential
role of Ets-1 in IL-18-regulated collagen expression,
cells were treated with Ets-1 small interfering RNA (siRNA)
for 24 hours, which resulted in a 60% reduction of Ets-1
protein levels (Figure 6b). Western blot analysis revealed
that Ets-1 siRNA was effective at reducing the level of Ets-1
protein. We then examined whether Ets-1 was involved in
IL-18-regulated collagen expression in HDF by transfecting
cells with Ets-1 siRNA or control siRNA and treating
cells with IL-18. Next, we analyzed collagen expression by
real-time PCR and western blotting. Ets-1 siRNA blocked the
inhibition of collagen gene and protein expression mediated
by IL-18 (Figure 6c and d). These results suggested that
IL-18-regulated collagen production is mediated through
Ets-1 activation.
IL-18 regulates collagen expression via the ERK pathway
Recent evidence suggests that activation of extracellular
signal-regulated kinase (ERK) inhibits type I collagen
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Figure 2. IL-18 inhibited COL1A1, COL1A2, and COL3A1 mRNA expression
and protein production in human dermal fibroblasts (HDFs). (a) HDFs were
treated with various doses of IL-18 for 6 hours, total RNA was extracted, and
cDNA was synthesized for quantitative real-time reverse transcriptase (RT)-
PCR. (b) Kinetics of IL-18-mediated collagen expression shown by real-time
RT-PCR of collagen mRNA expression in HDFs treated with IL-18
(200 ngml1) for p24 hours. (c) Cells were cultured in DMEM/1% FBS
medium and treated with the indicated concentration of IL-18. Protein levels
in supernatants were determined after 24 hours of culture. Total collagen was
detected by Sircol assay, each performed in triplicate. Data represent the
mean±SEM of three experiments. *Po0.05 versus control.
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Figure 3. IL-18 decreased collagen gene expression and production in an
IFN-c-dependent manner. (a) Human dermal fibroblasts (HDFs) were
pretreated with neutralizing anti-IFN-g antibody (5 mgml1) and cultured for
6 hours in the presence of IL-18 (200 ngml1) or IFN-g (1,000Uml1). Total
RNA was extracted, and real-time reverse transcriptase–PCR was performed.
(b) Cells were cultured in DMEM/1% FBS medium. Protein levels in
supernatants were determined after 24 hours of culture. Total collagen was
detected by Sircol assay, each performed in triplicate. Data represent the
mean±SEM of three experiments. *Po0.05 versus control, yPo0.05 versus
the IL-18-treated group.
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expression in dermal fibroblasts (Reunanen et al., 2000). We
investigated whether activation of mitogen-activated protein
kinases (MAPKs) is involved in IL-18-regulated collagen
expression. Pretreatment of cells with the ERK inhibitor
PD98059 blocked the inhibition of IL-18-regulated collagen
expression and production, whereas the p38 MAPK inhibitor
SB203580 and the JNK inhibitor SP600125 did not (Figure 7a
and b). These data show that the ERK-signaling pathway
participates in the regulation of collagen expression mediated
by IL-18.
Next, we investigated whether IL-18 treatment activates
ERK phosphorylation. Western blotting using anti-phospho-
ERK antibody revealed a transient phosphorylation of ERK
after 10minutes of treatment with IL-18 (Figure 7c). In
addition, PD98059 significantly blocked IL-18-induced
phosphorylation of ERK (Figure 7d). Because the transcription
factor Ets-1 is a known effector of MAPK (Ito et al., 2004), we
investigated whether ERK activation is involved in IL-18-
mediated Ets-1 protein induction. We found that pretreatment
of cells with PD98059 suppressed IL-18-regulated Ets-1
expression (Figure 7e). These results suggest that IL-18
downregulates collagen expression by altering levels of
Ets-1 through the ERK pathway.
IL-18 suppresses collagen production in SSc dermal fibroblasts
We also tested whether IL-18 could regulate collagen gene
expression and protein production in dermal fibroblasts
derived from patients with systemic sclerosis. As shown in
Figure 8a and b, IL-18 inhibited the synthesis of collagen
protein and mRNA in SSc dermal fibroblasts, which is in
accordance with the results using HDFs.
DISCUSSION
In this study, we investigated the regulatory effect of IL-18 on
the expression of type I and III collagen genes in HDFs. Our
results show that IL-18 inhibits collagen expression and
production in HDFs in an IFN-g-dependent manner. IL-18
regulates collagen production at the transcriptional level and
is dependent on Ets-1 activation. Moreover, our data show
that IL-18 inhibits collagen production via the ERK pathway.
Collagen accumulation is the hallmark of fibrosis. Several
polypeptide growth factors regulate tissue repair and fibrosis
(Eckes et al., 2000; Sorrell and Caplan, 2004). The develop-
ment of fibrosis requires the production of Th2 cytokines such
as IL-4, IL-5, IL-10, and IL-13; correlates with TGF-b
synthesis; and is suppressed by Th1 cytokines such as IL-12
and IFN-g (Wahl et al., 1997; Chiaramonte et al., 1999;
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Figure 4. IL-18 inhibited the collagen gene expression and production
induced by transforming growth factor (TGF)-b. (a) Human dermal
fibroblasts were pretreated with 10 ngml1 of TGF-b for 2 hours, before
addition of 200 ngml1 of IL-18. After 6 hours, collagen gene expression was
detected by real-time reverse transcriptase–PCR. (b) Protein levels in
supernatants were determined after 24 hours of culture. Total collagen was
detected by Sircol assay, each performed in triplicate. Data represent the
mean±SEM of three experiments. *Po0.05 versus control, yPo0.05 versus
the TGF-b-treated group.
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Figure 5. IL-18 reduced COL1A1 and COL1A2 promoter activity in human
dermal fibroblasts. Cells were transiently transfected with either the 2019
COL1A1/Luc promoter construct (a) or the 2027 COL1A2/Luc promoter
construct (b). At 16 hours after transfection, cells were treated with
transforming growth factor (TGF)-b (10 ngml1) for 2 hours and incubated in
the presence or absence of IL-18 (200 ngml1) for 24 hours. Data represent
the mean±SEM of three experiments. *Po0.05 versus control, yPo0.05
versus the TGF-b-treated group.
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Fallon et al., 2000; Farah et al., 2000; Hoffmann et al., 2000).
For example, it has been demonstrated that IFN-g can inhibit
the in vitro production of collagen by fibroblasts and
chondrocytes and can decrease type I and III procollagen
mRNA steady-state levels in these two types of cells (Sakaida
et al., 1999). TGF-b is a well-known inducer of collagen
synthesis, and agents antagonizing TGF-b-induced fibrosis
have been shown to block or attenuate experimentally
induced fibrosis (Wang et al., 1999; Yamamoto et al.,
1999). Therefore, strategies focused at neutralizing the most
fibrogenic cytokine, TGF-b, may provide a promising
approach to preventing excessive accumulation of collagen
in fibrosis. IL-18 has multiple functions, and it participates in
both Th1- and Th2-mediated responses. It has been demon-
strated that hepatic fibrosis is exacerbated by IL-18, which
activates CD4þ T cells, and this effect is blocked by
treatment with anti-IL-18. The proliferative effects of IL-18
on HSC cells might occur indirectly through TNF-a and IFN-b
in hepatic inflammation (Zhang et al., 2007). Reddy et al.
(2008) reported that IL-18 stimulates fibronectin expression in
primary human cardiac fibroblasts. Oku et al. (2008)
demonstrated that pirfenidone attenuated bleomycin-induced
pulmonary fibrosis in mice and that IL-18 contributed to this
antifibrotic effect of pirfenidone. On the basis of these
findings, IL-18 has been described as a fibrogenic cytokine.
However, other studies have shown that IL-18 can also
reverse fibrosis. Nakatani-Okuda et al. (2005) reported that
IL-18 plays a key role in protection against bleomycin-
induced lung injuries in mice. It is currently believed that the
imbalance of Th1 and Th2 responses is crucial in the
development of fibrosis. Zhang et al. (2001) reported that
intrasplenic transplantation of IL-18 gene-modified hepato-
cytes into S. japonicum–infected mice results in a significant
increase in IFN-g and IL-2 and a decrease in IL-4 and IL-10, in
both liver and serum. They also showed that it reverses
hepatic fibrosis and regulates Th1 and Th2 cytokine
responses. In this study, we have shown that IL-18-induced
inhibition of collagen synthesis occurred in an IFN-g-
dependent manner (Figure 3). Overall, the dual effects of
IL-18 as profibrotic or antifibrotic mediators of fibrosis seem
to depend on the induction of Th1 or Th2 cytokine profiles.
Our finding that IL-18-induced IFN-g mediates the regression
of collagen production suggests that IL-18 acts as an
antifibrotic mediator in skin. IL-18 may therefore represent
a class of modulators with potential usefulness for the
treatment of excessive fibrosis of the skin.
Recently, Ets-1 has been shown to modulate the transcrip-
tion of ECM genes, including type I collagen (Czuwara-
Ladykowska et al., 2002; Sherriff-Tadano et al., 2006).
Constitutive expression of Ets proteins has been associated
with cellular transformation of erythroblasts and fibroblasts
(Kola et al., 1993; Iwasaka et al., 1996; Reisdorff et al., 2002).
Several potential binding sites for transcription factors, such
as members of the Ets family, are located in the collagen
promoter, and it is thought that these factors are associated
with collagen gene expression (Znoyko et al., 2006; Peng
et al., 2008). Czuwara-Ladykowska et al. (2002) reported that
elevated expression of Ets-1 altered TGF-b induction of type I
collagen and other matrix-related genes in human fibroblasts
(Sherriff-Tadano et al., 2006), showing that Ets-1 may act as
an antagonist of the profibrotic effect of TGF-b. It is known
that overexpression of Ets-1 in cultured mesangial cells
suppresses the TGF-b-induced reduction of DNA-binding
activity (Mizui et al., 2006). (Iwasaka-Yagi et al., 2001) have
demonstrated that TGF-b attenuates the transactivity of Ets-1
by inhibiting the DNA binding of Ets-1. On the basis of this
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Figure 6. Ets-1 is involved in the inhibition of collagen expression after
treatment with IL-18. (a) Human dermal fibroblasts were collected after IL-18
(200 ngml1) treatment for 24 hours. Whole-cell lysates (30 mg per lane) were
probed with antibody against Ets-1 in western blots. (b) Cells were transfected
with siEts-1. After 24 hours, protein was extracted and Ets-1 was analyzed by
western blotting. Band intensities were quantitated. (c) Cells were transfected
with control siRNA or siEts-1. Cells were collected after IL-18 treatment for
6 hours. Total RNA was extracted and cDNA was synthesized for quantitative
real-time reverse transcriptase–PCR. (d) Cells were transfected with control
siRNA or siEts-1. Cells were harvested after IL-18 treatment for 24 hours, and
collagen production was analyzed by western blotting using anti–type I
collagen antibody. Band intensities were quantitated.
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knowledge, we can predict that Ets-1 suppresses TGF-b-
induced inhibition of DNA binding and TGF-b-induced
collagen synthesis. Ets-1 is a potent suppressor of TGF-b-
induced genes. In this study, levels of Ets-1 protein were
increased by treating fibroblasts with IL-18, and Ets-1 siRNA-
blocked IL-18-induced inhibition of collagen expression.
These results suggest that Ets-1 is a potent repressor of
collagen production.
Members of the MAPK family, including ERK, p38 MAPK,
and JNK, are frequently involved in TGF-b-induced
fibrosis. The activity of MAPKs varies depending on cell
type, culture conditions, and ambient levels of other
cytokines (Westermarck and Kahari, 1999; Reunanen et al.,
2000). ERK has been identified as a potent negative
regulatory pathway with respect to the expression of type I
collagen in fibroblasts, suggesting its role in the control of
collagen deposition in processes such as wound repair and
tumor growth (Reunanen et al., 2000). It has been shown that
Ets-1, a known effector of MAPKs, is a downstream target of
ERK and has an important role in the regulation of gene
expression related to the growth and migration of endothelial
cells (Ito et al., 2004; Munoz-Chapuli et al., 2004). In this
study, we showed that IL-18 regulates collagen gene
expression and soluble collagen production in HDFs via the
alteration of Ets-1 activation through the ERK pathway.
Fibroblasts from affected SSc cells cultured in vitro
produced excessive amounts of various collagens, mainly
type I and III collagens. Recently, Sherriff-Tadano et al. (2006)
reported that inhibition of collagen synthesis induced by
HGFs was due in part to the enhanced action of IFN-g, an
antifibrotic cytokine. We observed that IL-18 inhibited
collagen synthesis in SSc dermal fibroblasts. Our data suggest
that IL-18 could serve as a potential therapeutic target for
patients with sclerosis.
In conclusion, we have demonstrated that IL-18 decreases
collagen expression in HDF through an Ets-1-dependent
pathway and through the phosphorylation of ERK. We have
also shown that IL-18 inhibits TGF-b-induced collagen
production. These findings provide an insight into the
involvement of IL-18 with the mechanism of fibrosis. Our
data suggest that IL-18 can act directly on dermal fibroblasts
and may have antifibrotic action in fibrosis.
MATERIALS AND METHODS
Cell culture and stimulation
HDFs from neonatal foreskin were obtained from the American Type
Culture Collection (CRL-2097, Manassas, VA). The cells were
cultured in DMEM (Gibco-BRL, Gaithersburg, MD) supplemented
with antibiotics (100Uml1 penicillin G and 100 mgml1 strepto-
mycin) and 10% heat-inactivated fetal bovine serum (FBS,
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Figure 7. IL-18 induced extracellular signal-regulated kinase (ERK) activation. (a) Human dermal fibroblasts were serum starved for 16 hours and
pretreated with 10 mM of ERK inhibitor PD98059, 10 mM of p38 inhibitor SB203580, or 20mM of JNK inhibitor SP600125 for 2 hours before the addition of
200 ngml1 of IL-18. After incubations, collagen gene expression was detected by real-time reverse transcriptase–PCR. (b) Cells were treated with IL-18
(200 ngml1, 24 hours) in the presence of PD98059 (10 mM), SB203580 (10mM), or SP600125 (20 mM). Total collagen was detected by Sircol assay, each
performed in triplicate. Data represent the mean±SEM of three experiments. *Po0.05 versus control, yPo0.05 versus the IL-18-treated group. (c) Cell lysates
from cells incubated in the presence of IL-18 (200 ngml1) for the indicated times were subjected to western blotting with an anti-phospho-ERK antibody or
an anti-total-ERK antibody. (d) Cells were incubated with PD98059 (10 mM) for 2 hours before the addition of IL-18 (200 ngml1). After 10minutes, cells
were harvested and phosphorylation of ERK was analyzed by western blotting. (e) Cells were incubated with PD98059 (10 mM) for 2 hours before the addition
of IL-18 (200 ngml1). After 24 hours, cells were harvested and Ets-1 was analyzed by western blotting using anti-Ets-1 antibody.
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Gibco-BRL) in a humidified atmosphere containing 5% CO2 at
37 1C. This cell line was used for experiments while in their log
phase of growth. The cells were used at passages 4–11.
SSc dermal fibroblasts were obtained from Chul Soo Cho
(Division of Rheumatology, Department of Internal Medicine,
School of Medicine, Catholic University of Korea, South Korea).
The ethics committee of the Catholic University of Korea approved
the study, and all patients provided informed consent. The study was
designed and conducted in accordance with the Declaration of
Helsinki. SSc fibroblasts were collected from three volunteer patients
and were maintained in DMEM containing 10% FBS, penicillin, and
streptomycin. When cells approached confluence, they were
detached with trypsin and subcultured until use. Cells were seeded
in six-well plates in DMEM supplemented with 10% FBS at 37 1C in
a humidified (5% CO2) incubator. Only cells from passages 3–7 were
analyzed in this study.
Cells were seeded at a density of 5 105 cells per 100-mm dish.
After 24 hours, they were washed with a serum-free medium and
then placed in a medium without FBS for at least 16 hours before the
start of experiments. In some experiments, cells were pretreated with
10 mM SB203580 (Sigma, St Louis, MO), a p38 MAPK inhibitor; 10 mM
PD98059 (Sigma), an ERK inhibitor; 20 mM SP600125 (Sigma), a JNK
inhibitor; or TGF-b (10 ngml1) (R&D Systems, Minneapolis, MN)
for 2 hours, before the addition of 200 ngml1 of recombinant
human IL-18 (MBL, Nagoya, Japan).
HDF cells were plated in six-well plates; thereafter, confluent
cells were treated with IL-18 (200 ngml1) or IFN-g (1,000Uml1)
for 24 hours in the presence or absence of 5 mgml1 monoclonal
human IFN-g antibody (R&D Systems). The antibody—mouse
monoclonal isotype IgG1—was shown to specifically neutralize
the biological activity of rIFN-g according to the manufacturer’s
reference. After incubation, collagen gene expression and soluble
collagen were determined as described.
Reverse transcriptase–PCR
After experimental treatment, total RNA was isolated using Trizol
reagent (Invitrogen, Carlsbad, CA). One microgram of total RNA was
used for first-strand cDNA synthesis using M-MLV reverse tran-
scriptase (Promega, Madison, WI) according to the manufacturer’s
instructions. The primers used for PCRs are shown in Supplementary
Table S1. The PCR amplification consisted of 32 cycles of 94 1C for
30 seconds, 58 1C for 30 seconds, and 72 1C for 1minute. RT-PCRs
were performed using 2 PCR Master Mix Solution (i-Taq, iNtRON
Biotechnology, Seongnam, Korea). The PCR products were sub-
jected to electrophoresis on 1.5% agarose gel and visualized with
ethidium bromide.
Flow cytometry analysis
Indirect FACS analysis was performed to detect IL-18R expression.
Briefly, cells were washed twice with phosphate-buffered saline and
stained with mouse anti-human IL-18R antibody (R&D Systems) for
30minutes on ice. Cells were further stained with fluorescein
isothiocyanate–conjugated goat anti-mouse IgG antibody for 30min-
utes on ice, followed by two washes with phosphate-buffered saline.
A FACScan (Becton Dickinson, Mountain View, CA) flow cytometer
was used for analysis.
Collagen promoter–reporter assay
We used genomic DNA derived from HDFs as a template. For
generating the COL1A1-luciferase construct in the pGL2 vector, a
2,040-bp fragment containing the sequences from 2,019 to þ 21 of
human COL1A1 promoter was amplified by PCR from a COL1A1/
Luc plasmid. Similarly, for generation of COL1A2-Luc, a 2,039-bp
fragment containing the sequence from 2,027 to þ 372 was
amplified by PCR from genomic DNA. The primers were designed
according to the genomic sequence of human chromosome 17
(GenBank accession no. NC 000017.9) for COL1A1 and the
genomic sequence of human chromosome 7 (GenBank accession
no. NC 000007.12) for COL1A2 (Supplementary Table S1). The
products specific for the COL1A1 and COL1A2 gene were digested
with KpnI, XhoI, and HindIII, and then subcloned into a promoterless
luciferase expression plasmid, pGL2-basic (Promega). These con-
structs were verified by sequencing. The plasmid DNA used for
transfection was prepared using an endotoxin-free DNA Maxiprep
Kit (Qiagen, Hilden, Germany). Transcription factor cluster analysis
was performed using the MatInspector program (http://www.
genomatix.de/products/MatInspector/index.html).
Cells were transfected with an equal amount of total plasmid
DNA containing the COL1A1 or COL1A2 promoter construct
by using Lipofectamine 2000 (Invitrogen) according to the
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Figure 8. IL-18 inhibited collagen gene expression and production in
systemic sclerosis (SSc) dermal fibroblasts. (a) SSc dermal fibroblasts were
pretreated with or without TGF-b (10 ngml1) for 2 hours and incubated in the
presence or absence of IL-18 (200 ngml1) or IFN-g (1,000Uml1) for
6 hours. Total RNA was extracted, and cDNA was synthesized for quantitative
real-time reverse transcriptase–PCR. (b) Cells were cultured in serum-free
medium. The protein in supernatants was assessed after 24 hours of culture.
Total collagen was detected by Sircol assay, each performed in triplicate.
Data represent the mean±SEM of three experiments. *Po0.05 versus control,
yPo0.05 versus the transforming growth factor-b-treated group.
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manufacturer’s guidelines. The DNA/lipofectamine mixture was
removed 4hours later, and cells were placed in a serum-free
medium. Unless stated otherwise, cells were treated 12 hours after
transfection with recombinant human TGF-b and/or IL-18 for
24 hours. Luciferase activity was measured using Promega’s Lucifer-
ase Assay System according to the manufacturer’s instructions. All
transfections were performed in triplicate. Luciferase activity was
determined using a luminometer (Wallac MicroBeta Trilux, EG &
Berthold, Bad Wildbad, Germany). Total cellular protein was
determined using a protein assay kit (Bio-Rad Laboratories,
Hercules, CA). Reporter activities were expressed as relative light
units normalized to total cellular protein.
RNAi and transfection
Control siRNA and Ets-1 siRNA were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). HDFs at 70% confluence were
transfected with siRNA (40 pmol) using the Nucleofector apparatus
(AMAXA, Ko¨ln, Germany) as described by the manufacturer. After
16 hours of incubation in serum-free DMEM, cells were incubated in
the presence or absence of 200 ngml1 recombinant human IL-18.
Assays were carried out 6 or 24 hours later, and knockdown of
protein was confirmed by western blotting. Cells were harvested
after IL-18 treatment for 6 hours, and collagen expression was
detected by real-time RT-PCR. After 24 hours, cells were harvested,
and collagen production was analyzed by western blot using
anti–type I collagen antibody (Southern Biotechnology, Birmingham,
AL) and anti-g-tubulin antibody (Santa Cruz Biotechnology).
Quantitative real-time PCR
Total RNA was isolated with Trizol (Invitrogen). One microgram of
total RNA was used for first-strand cDNA synthesis using M-MLV
reverse transcriptase (Promega) according to the manufacturer’s
instructions. The primers used for PCRs are shown in Supplementary
Table S1. Real-time PCR was performed with a Rotor-Gene 3000
instrument (Corbett Life Science, Sidney, Australia) using SYBR
Premix Ex Taq (Takara, Shiga, Japan). Reaction mixtures were
incubated for 40 cycles at 95 1C for 15 seconds, 58 1C for 45 seconds,
and 72 1C for 20 seconds. The relative amounts of gene expression
were calculated by using the expression of b-actin as an internal
standard. Each sample was assayed in triplicate. For relative
quantification, the cycle threshold (Ct) method (ratio¼ 2-[Ct (COL)-
Ct (b-actin)]) was used.
Measurement of total collagen
Total soluble collagen was quantified using the Sircol soluble
collagen assay (Biocolor, Newtownabbey, UK). Briefly, confluent
cells in six-well plates were incubated for 24 hours with 1ml DMEM/
1% FBS. After the experimental treatment, cell supernatants were
collected by centrifuging at 1,500 r.p.m. for 5minutes. One milliliter
of Sircol dye was added to 200ml of supernatant and incubated for
30minutes, followed by centrifuging at 10,000 r.p.m. for 10minutes,
to drop the formed collagen–dye complex. After removing the
suspension, droplets were dissolved in 1ml Sircol alkali reagent and
relative absorbance was measured at 540 nm.
Western blot analysis
After two washes with cold phosphate-buffered saline, cells were
lysed in lysis buffer (50mM Tris-HCl (pH 7.5), 1mM EDTA, 1mM
EGTA, 150mM NaCl, 1% Nonidet P-40, 0.1% sodium dodecylsulfate
(SDS), 1mM Na3VO4, 1mgml
1 leupeptin, and 1mM phenylmethyl-
sulfonyl fluoride (PMSF)). Protein concentration was measured using
a Bio-Rad Protein Assay Kit (Bio-Rad Laboratories). Thirty micro-
grams of protein was directly separated by 10% SDS-PAGE and
transferred to polyvinylidene difluoride (PVDF, Bio-Rad Labora-
tories). Blocked membranes were then incubated with primary
antibodies (goat anti–type I collagen or goat anti-g-tubulin antibodies
at a final concentration of 1:500, anti-phospho-ERK or anti-ERK
rabbit polyclonal antibodies (Cell Signaling, Beverly, MA) at a final
concentration of 1:1,000, or anti-Ets-1 rabbit polyclonal antibody
(Santa Cruz Biotechnology) at a final concentration of 1:200)
overnight at 4 1C, washed three times with TBS containing 0.1%
Tween 20, and subsequently incubated with a horseradish perox-
idase–conjugated anti-goat or anti-rabbit secondary antibody
(1:2,000) for 1 hour at room temperature. Bands were visualized
using an enhanced chemiluminescence detection system (Amer-
sham Biosciences, Piscataway, NJ). Band intensities were quantified
using the Bio-Rad imaging system, and the quantity of phosphory-
lated proteins was expressed as a ratio of phosphorylated to total
protein in each sample. Blots were stripped and re-probed with
g-tubulin antibody to confirm equal protein loading.
Statistical analysis
Statistical significance was determined using Student’s t-test. Mean
differences were considered to be significant when Po0.05. Results
are shown as the mean±SEM.
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